- Home
- DAKT vs KURA Comparison
DAKT vs KURA Comparison
Compare DAKT & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DAKT | KURA |
|---|---|---|
| Founded | 1968 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 944.7M | 841.6M |
| IPO Year | 1996 | 2015 |
Fundamental Metrics
Financial Performance| Metric | DAKT | KURA |
|---|---|---|
| Price | $20.09 | $10.96 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $25.56 |
| AVG Volume (30 Days) | 477.1K | ★ 1.9M |
| Earning Date | 03-04-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 538.10 | N/A |
| EPS | ★ 0.92 | N/A |
| Revenue | ★ $608,932,000.00 | $67,482,000.00 |
| Revenue This Year | $12.06 | $28.28 |
| Revenue Next Year | $9.16 | $106.37 |
| P/E Ratio | $21.23 | ★ N/A |
| Revenue Growth | 6.89 | ★ 25.24 |
| 52 Week Low | $14.87 | $5.45 |
| 52 Week High | $28.27 | $12.49 |
Technical Indicators
Market Signals| Indicator | DAKT | KURA |
|---|---|---|
| Relative Strength Index (RSI) | 51.53 | 66.85 |
| Support Level | $19.08 | $8.72 |
| Resistance Level | $20.55 | $11.29 |
| Average True Range (ATR) | 1.07 | 0.49 |
| MACD | -0.05 | 0.18 |
| Stochastic Oscillator | 41.18 | 95.67 |
Price Performance
Historical ComparisonAbout DAKT Daktronics Inc.
Daktronics Inc designs and manufactures electronic scoreboards, programmable display systems, and large-screen video displays for sporting, commercial, and transportation applications. It is engaged in a full range of activities: marketing and sales, engineering and product design and development, manufacturing, technical contracting, professional services, and customer service and support. The company offers a complete line of products, from small scoreboards and electronic displays to large multimillion-dollar video display systems as well as related control, timing, and sound systems. The company has five reportable segments: Commercial, Live Events, High School Park and Recreation, Transportation, and International. The company makes the majority of its revenue from Live events.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.